NCT02639910 - Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

November 30, 2018

Study Completion Date

December 31, 2021

Conditions

Leukemia, Lymphocytic, Chronic, B-CellChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Interventions

BIOLOGICAL

Tafasitamab

tafasitamab (MOR208) dose: 12 mg/kg intravenous infusion

DRUG

Idelalisib

idelalisib dose: 150 mg twice daily orally

DRUG

Venetoclax

venetoclax dose: 400 mg once daily orally

Trial Locations (17)

1090

Clinical Study Site, Vienna

1307

Clinical Study Site, Dresden

4103

Clinical Study Site, Leipzig

5020

Clinical Study Site, Salzburg

8036

Clinical Study Site, Graz

20162

Clinical Study Site, Milan

25123

Clinical Study Site, Brescia

30510

Clinical Study Site, Krakow

32204

Clinical Study Site, Jacksonville

43210

Clinical Study Site, Columbus

45372

Clinical Study Site, Opole

55905

Clinical Study Site, Rochester

80804

Clinical Study Site, München

80952

Clinical Study Site, Gdansk

85094

Clinical Study Site, Lublin

BH7 7DW

Clinical Study Site, Bournemouth

LS9 7TF

Clinical Study Site, Leeds